# Zilovertamab vedotin PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zilovertamab-vedotin

> The next catalyst for zilovertamab vedotin, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Sep to Dec 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | zilovertamab vedotin |
| Codes | MK-2140, VLS-101 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Chronic Lymphocytic Leukemia](https://sec-api.dev/indications/chronic-lymphocytic-leukemia), [Lymphoma, Large B-Cell, Diffuse (DLBCL)](https://sec-api.dev/indications/lymphoma-large-b-cell-diffuse-dlbcl), Relapsed or Refractory Diffuse Large B-Cell Lymphoma, [Lymphoma, Large B-Cell, Diffuse](https://sec-api.dev/indications/lymphoma-large-b-cell-diffuse), DLBCL, [Diffuse Large B-Cell Lymphoma](https://sec-api.dev/indications/diffuse-large-b-cell-lymphoma) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 21, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05144841 (A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05144841

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: DLBCL; Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05139017 (A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05139017

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: DLBCL; Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05139017 (A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05139017

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Lymphoma, Large B-Cell, Diffuse.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06890884 (A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06890884

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Lymphoma, Large B-Cell, Diffuse.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06890884 (A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06890884

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Lymphoma, Large B-Cell, Diffuse (DLBCL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05406401 (A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-04-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05406401

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Lymphoma, Large B-Cell, Diffuse (DLBCL).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05406401 (A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-04-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05406401

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05458297 (A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-05-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05458297

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05458297 (A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-05-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05458297

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06717347 (A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06717347

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diffuse Large B-Cell Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06717347 (A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06717347

## Same indication

- [Calquence (acalabrutinib)](https://sec-api.dev/pdufa/acalabrutinib) (AZN)
- [APG2575](https://sec-api.dev/pdufa/apg2575) (AAPG)
- [Emavusertib](https://sec-api.dev/pdufa/emavusertib) (CRIS)
- [TEPKINLY (epcoritamab)](https://sec-api.dev/pdufa/epcoritamab) (GMAB)
- [Imbruvica (ibrutinib)](https://sec-api.dev/pdufa/ibrutinib) (ABBV)
- [Nemtabrutinib](https://sec-api.dev/pdufa/nemtabrutinib) (MRK)
- [Jaypirca (pirtobrutinib)](https://sec-api.dev/pdufa/pirtobrutinib) (LLY)
- [BEQALZI™ (sonrotoclax)](https://sec-api.dev/pdufa/sonrotoclax) (ONC)
- [Tacabrutideg](https://sec-api.dev/pdufa/tacabrutideg) (ONC)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)

Calendar months: [September 2027](https://sec-api.dev/fda-calendar/2027-09), [December 2027](https://sec-api.dev/fda-calendar/2027-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zilovertamab-vedotin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zilovertamab vedotin PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zilovertamab-vedotin

```bibtex
@misc{secapidev_pdufa_zilovertamab_vedotin_20261116,
  title        = {Zilovertamab vedotin PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zilovertamab-vedotin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zilovertamab_vedotin_20261116","title":"Zilovertamab vedotin PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zilovertamab-vedotin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
